Miravant eyes priority review for SnET2
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Miravant is requesting a priority review for its SnET2 (rostaporfin) for treatment of wet age-related macular degeneration with any classic component. The March 31 submission meets the firm's previously announced first-quarter 2004 filing target (1Pharmaceutical Approvals Monthly Dec. 1, 2003, p. 7). The NDA is based on subset analyses of Phase III studies; Pharmacia opted out of its development agreement in January 2002 when the photodynamic therapy did not meet the primary endpoint in the overall study population. A Premarket Approval Application for the ophthalmic laser that activates rostaporfin was submitted in conjunction with the NDA...
You may also be interested in...
Miravant SnET2 NDA Filing Target Is Q1 2004; Funds Could Run Out Mid-Year
Miravant is planning to submit an NDA for its SnET2 PhotoPoint photodynamic therapy for wet age-related macular degeneration in the first quarter of 2004, according to a Nov. 14 quarterly report filed with the Securities & Exchange Commission.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.